Summary

Market Overview
Global Usher Syndrome Treatment Market reached US$ 1.6 billion in 2022 and is expected to reach US$ 2.3 billion by 2030, growing with a CAGR of 4.6% during the forecast period 2023-2030.
The global usher syndrome treatment market has experienced significant growth and transformations over the years, with various factors influencing its dynamics. Usher syndrome is a form of retinitis pigmentosa (RP), with associated deafness. According to the University of Michigan Health, usher syndrome is the cause of approximately 10% of all hereditary deafness, with deafness existing at birth or developing soon afterward.
Moreover, currently, there is no cure for the syndrome, but there are distinct ways are used to manage the usher syndrome. The management of usher syndrome commonly includes hearing aids, vision aids, cochlear implants, vitamin A supplements, speech therapy, physical therapy, occupational therapy, and others. Hearing aids are most commonly used for the management of usher syndrome.
Hearing aids are expected to account for the largest market share. Similarly, North America is expected to dominate the usher syndrome treatment market, capturing the largest market share of over the forecast period. According to the Cleveland Clinic Organization, about 4 to 17 per 100,000 children are born with usher syndrome and it's the cause of deafness in 3% to 6% of all children who are deaf. To inherit the disease, both of the parents must carry the gene that causes usher syndrome.
Owing to the increasing prevalence of usher syndrome, increasing awareness about the usher syndrome and their treatments, rising clinical trials and regulatory approvals for novel therapeutics, and advancements in hearing aids and cochlear implants are the major factors expected to drive the growth of the global usher syndrome treatment market over the forecast period.
Market Dynamics
Rising Clinical Trials and Regulatory Approvals for Novel Therapeutics Expected to Drive the Growth of the Usher Syndrome Treatment Market
The ongoing clinical trials and regulatory approvals plays an important role in the development of novel therapeutics, which is expected to drive the market share over the forecast period. Clinical trials are very essential for testing the safety and efficacy of new usher syndrome therapeutic approaches, including drugs, medical devices, gene therapies, and other interventions. As more research and development efforts are focused on finding effective treatments for Usher syndrome, an increase in clinical trials indicates a growing interest in addressing this rare genetic disorder.
For instance, on April 10, 2023, Dallas-based Nacuity launched a Phase I/II clinical trial in Australia for its oral antioxidant therapy. The trial is for people with Usher syndrome. The Foundation Fighting Blindness is investing up to $7.5 million to advance the promising, emerging drug for retinitis pigmentosa, Usher syndrome, and related conditions. Known as N-acetylcysteine-amide (NACA), the molecule is designed to slow vision loss by protecting retinal cells from oxidative stress.
Regulatory approvals such as FDA also plays a crucial role in the development of new therapeutics for the better management of the usher syndrome. When a novel therapeutic receives regulatory approval, it signifies that the treatment has met rigorous standards for safety and effectiveness. Such approvals are not only important for patient access to new therapeutics but also for attracting investment and fostering further research in the field of usher syndrome treatment.
Increasing Awareness Also Expected to Drives the Growth of the Usher Syndrome Treatment Market
The increasing awareness about usher syndrome drives the usher syndrome treatment market over the forecast period. The awareness campaigns helps to educate healthcare professionals and the public about the symptoms and early signs of usher syndrome, which may helps in early management. Early detection and diagnosis allows for timely intervention, which can potentially slow the progression of the disease and improve the effectiveness of treatments.
For instance, according to the usher syndrome coalition, the third Saturday in September is Usher Syndrome Awareness Day. Usher Syndrome Awareness Day seeks to bring attention to the most common genetic cause of combined deafness and blindness. By raising awareness around the world, able to connect those living with Usher syndrome and accelerate research towards treatments and a cure.
The awareness campaigns and patient advocacy groups are dedicated to usher syndrome early detection, diagnosis, and management. These groups play a vital role in raising awareness, providing support to affected individuals and their families, and driving initiatives to accelerate research and treatment development. Strong advocacy efforts can attract attention from researchers and healthcare stakeholders, leading to increased collaboration and progress in therapeutic developments.
Insufficient Funding for Usher Syndrome Therapeutics Hampers the Market Growth
The lack of funding for usher syndrome therapeutics hampers the global usher syndrome treatment market over the forecast period. Insufficient funding for research and development can disrupt the discovery of new therapeutic approaches for usher syndrome treatment. Insufficient funding for R&D investments may result in fewer innovative treatments being developed, limiting the treatment options available to individuals with usher syndrome and hindering advancements in the field.
Clinical trials also plays a crucial role in novel therapeutics, the lack of funding may also impact the conducting of clinical trials. Clinical trials require funding to recruit and enroll participants, conduct the trials, and analyze the results. This reduced healthcare expenditure can lead to fewer clinical trials being conducted, limiting the opportunities for individuals with usher syndrome to participate in research that could lead to better management of the disease.
High Treatment Costs Also Hampers the Growth of the Market
The high treatment costs can hamper the market growth over the forecast period. And these high treatment costs make timely treatments inaccessible to a significant portion of the population due to the limited insurance coverage, and especially those limited financial resources. This limited access could result in a smaller patient pool and, consequently, lower demand for treatments due to the cost restraints.
For instance, according to the usher syndrome coalition, the cost and turn-around time of a genetic test may vary depending on the lab and the methods used for testing. Some usher screens cost around $500. More accurate and detailed testing may cost between $2000-$5000. A typical range of time to get the results might be 8-12 weeks and the treatment also costs much.
Healthcare providers might be hesitant to recommend or administer treatments with high costs, especially if there are alternative treatments available that are more affordable. This could result in reduced adoption of the available treatments which further leads to the hampering market growth.
Segment Analysis
The global usher syndrome treatment market is segmented based on disease type, treatment type, end-user, and region.
The Hearing Aids from the Treatment Segment Accounted for Approximately 37.6% of the Market Share
There is no specific treatment or cure for usher syndrome, but hearing aids plays a significant role in the management of hearing loss in usher syndrome patients. Children with type 3 usher syndrome often develop hearing loss by adolescence, requiring hearing aids by mid-to-late adulthood for the management of hearing loss. Hearing aids play a role by amplifying sounds, making them louder and easier for individuals with hearing loss to perceive. This can improve their ability to communicate and engage with their surroundings.
For instance, on August 17, 2022, Lucid Hearing, LLC, a market leader and global provider of advanced hearing technology and audio solutions, commends the Food and Drug Administration (FDA) for its efforts to give Americans expanded access to hearing solutions. The ruling as finalized by the FDA creates a new over-the-counter (OTC) category which allows hearing aids to be sold directly online and in stores to consumers without requiring a medical visit, audiogram test, or prescription.
Moreover, hearing aids helps usher syndrome patients by restoring or enhancing hearing and hearing aids can also improve an individual's overall quality of life with better and enhanced management of hearing loss. They can participate more fully in conversations, social interactions, and daily activities by using hearing aids. Early identification and fitting of hearing aids for individuals with Usher syndrome can contribute to better hearing, speech and language development in children.
Geographical Penetration
North America Accounted for Approximately 41.8% of the Market Share in 2022, Owing to the Advanced Healthcare Infrastructure and Strong Presence of Major Players
North America region holds the largest market share over the forecast period especially due to the advanced and well-established healthcare infrastructure and the strong presence of major players in the region. North America, especially in the United States and Canada, is well-known for its advanced healthcare infrastructure which includes hospitals, ophthalmic clinics, ENT clinics, and others, which facilitates early detection, diagnosis, and better management of usher syndrome. This encompasses market dominance in the region.
Moreover, many key global major players in the region including pharmaceutical companies, organizations, and research institutions facilitate conducting clinical trials and research activities which enhance innovative treatment options for better management. Their strong presence can contribute to the growth and expansion of the market, as they bring expertise, resources, funding, and investments into the region, leading to market dominance in the region.
For instance, on October 18, 2022, Eli Lilly and Company and Akouos, Inc. announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss including multiple inner ear conditions such as AK-CLRN1 for Usher Type 3A, an autosomal recessive disorder characterized by progressive loss of both hearing and vision.
Competitive Landscape
The major global players in the usher syndrome treatment market include MED-EL, Audina Hearing Instruments, Inc., Sonova, Earsmate, Ototronix Diagnostics, Rion Co. Ltd., Cochlear Ltd, Tobii Dynavox US, Enhanced Vision, and Nurotron Biotechnology Co. Ltd among others.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created many challenges for the healthcare industries worldwide, including the global usher syndrome treatment market. During the pandemic, most of the countries faced more challenges due to the lockdown restrictions, supply chain disruptions, and reduced research activities and clinical trials are seen, which significantly impacted the global market.
The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting on developing the innovative treatment options. Major pharmaceutical industries faced challenges in conducting clinical trials for the usher syndrome treatment due to redirection towards COVID-19 pandemic treatment.
The COVID-19 pandemic severely disrupted global supply chains, impacting the transportation of raw materials such as hearing aids, visual aids, and other medical devices used in the treatment of usher syndrome. Movement restrictions and border closures delayed shipments and caused production delays. Additionally, some countries faced shortages of raw materials due to disruptions in their supply chain networks.
With the outbreak of the pandemic, telecommunication has improves and helped in many ways. Telecommunication is a positive impact that helps the patients for timely consultation for the rural people. However, these measures explained the impact of the COVID-19 pandemic on global usher syndrome treatment market.
Russia-Ukraine Conflict Analysis
The Russia-Ukraine conflict is estimated to have a moderate impact on the global usher syndrome treatment market. Many clinical trials and research activities are temporarily disrupted which is directly impacted the development of novel therapeutics for the treatment of usher syndrome.
The conflict has less impact mainly due to the low prevalence in the region and the absence of key market players in this region. The conflict also affected the supply chains and transportation of raw materials and medical devices which are used in the treatment of the usher syndrome.
By Disease Type
• Type 1
• Type 2
• Type 3
By Treatment Type
• Hearing Aids
• Cochlear Implants
• Vision Aids
• Speech Therapy
• Physical Therapy
• Occupational Therapy
• Vitamin A Supplements
• Others
By End-User
• Hospitals
• Ophthalmic Clinics
• ENT Clinics
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• On June 06, 2023, AAVantgarde Bio, a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, announced the closing of a €61 million Series A financing. The financing was co-led by US biotechnology venture creation firm Atlas Venture and European life sciences venture capital investment firm Forbion, with participation from Longwood Fund and the Company’s founding investor Sofinnova Partners through its Sofinnova Telethon Fund. The company is validating the platforms in two lead programs, Usher Syndrome Type 1 B associated retinitis pigmentosa (Usher1B), using dual hybrid, and Stargardt disease, using AAV intein.
• On September 13, 2022, Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts, and other diseases caused by oxidative stress, and Arctic Therapeutics International, precision-based drug development and diagnostic testing company using genetic and genealogy information to guide therapeutic development, announced the companies have entered into an exclusive licensing agreement and strategic partnership for the development and commercialization of NPI-001 in Iceland. NPI-001 has been granted orphan designation by the U.S. Food and Drug Administration for the treatment of retinitis pigmentosa in Usher Syndrome and is currently being evaluated in a Phase 1/2 clinical trial for Usher Syndrome
• On October 31, 2022, Platform technology company Replay launched Eudora, a gene therapy company targeting genetic diseases of the retina. Eudora will utilize Replay’s high payload capacity herpes simplex virus (HSV) vector to deliver gene therapy payloads, the company announced. Replay plans to launch four companies using this technology, although Eudora is the first to launch. The other three will focus on brain, skin, and muscle diseases. Eudora is initially focused on retinitis pigmentosa, Stargardt disease, and Usher syndrome type 1B.
DataM Intelligence Opinion:
According to the DataM Intelligence, the usher syndrome treatment market experiencing the rapid growth in recent years and is expected to grow rapidly in the coming years due to its increasing demand for novel therapeutic innovations for better patient outcomes. Many innovative treatment options are going to develop in the coming years by reducing the adverse effects and for effective treatment by controlling hearing loss and vision loss. Moreover, many clinical trials and research activities are still going on for novel therapeutics, which is expected to growth of the global usher syndrome treatment market in the upcoming years.
Why Purchase the Report?
• To visualize the global usher syndrome treatment market segmentation based on disease type, treatment type, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of usher syndrome treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global usher syndrome treatment market report would provide approximately 61 tables, 58 figures, and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents